Analyst Upgrades

• Walgreen (WAG) and Triumph Group (TGI) to buy from neutral at UBS.
• Focus Media (FMCN) to buy from neutral at Goldman.
• Home Depot (HD) to outperform from market perform at FBR Capital.
• Arbitron (ARB) to overweight from neutral at JPMorgan.
• Waddell & Reed (WDR) and Legg Mason (LM) to overweight from equal weight, and Janus Capital (JNS) to overweight from underweight, at Barclays.
• Central Euro Media (CETV) to buy from hold at Deutsche Bank.
• GenOn Energy (GEN) and Ntelos (NTLS) to outperform from sector perform at RBC Capital.
• Cooper Tire (CTB) to buy from neutral and Goodyear Tire (GT) to buy from underperform at BofA/Merrill.

Analyst Upgrades

• Deutsche Bank upgraded EMC (EMC) to buy from hold after channel checks indicated storage demand remains solid. The firm sees potential upside in 2011 from the company's new products and upped its target for shares to $25 from $20.
• BB&T upgraded American Commercial (ACLI) to buy with a $50 target based on pricing leverage and cost reductions.
• Argus upgraded Abercrombie (ANF) to buy with a $52 target based on accelerating comps.
• PerkinElmer (PKI) was upgraded to equal weight from underweight at Barclays.
• Valeant (VRX) was upgraded to market perform from underperform at Wells Fargo with a $26 to $28 valuation range.
• Blackrock (BLK) was upgraded to buy from hold at Deutsche Bank.

Investors pushed up call option prices in the medical instruments and supplies industry and pushed up put option prices in the diversified utilities industry Wednesday.

Any time the volatility skews above 1.00, it is an indication that calls are more expensive than puts. Typically, when calls are more expensive than puts, it means the demand for calls is greater than the demand for puts because investors believe the stock is going to rise in the future and they want to take advantage of that movement by buying calls.

The opposite is also true. Any time a volatility skews below 1.00, it is an indication that puts are more expensive than calls.

Analyst upgrades:

• Thomas Weisel upgraded PerkinElmer (NYSE: PKI) to Overweight from Market Weight on valuation as it sees limited downside to consensus estimates. The firm raised its target on shares to $20 from $18.
• Jefferies upgraded WuXi PharmaTech (NYSE: WX) to Hold from Underperform following the Q2 results as it believes the company's cross-selling strategy is paying off. The firm raised its target on shares to $12 from $5.
• FBR Capital upgraded J. Crew (NYSE: JCG) to Outperform from Market Perform to reflect the company's trend-right product, inventory control, unit growth, and strong management. The firm raised its target on shares to $36 from $25.
• Popular (NASDAQ: BPOP) was upgraded to Buy from Neutral at B. Riley.
• Pan American Silver (NASDAQ: PAAS) was upgraded to Buy from Neutral at UBS.
• HearUSA (AMEX: EAR) was upgraded to Buy from Hold at Roth Capital.

• Citigroup upgraded MEMC Electronic (NYSE: WFR) to Buy from Hold after channel checks indicated solar poly price pressures are easing. The firm added MEMC to its Top Picks Live list and raised its price target on shares to $24 from $15.
  
• FBR Capital upgraded PHH Corp (NYSE: PHH) to Outperform from Market Perform to reflect an improvement in mortgage banking fundamentals and recent management changes at the company. The firm raised its target on shares to $23 from $13.
  
• Deutsche Bank upgraded PerkinElmer (NYSE: PKI) to Hold from Sell on valuation, seeing a balanced risk/reward at current levels. The firm raised its target on shares to $19 from $14.
• Pearson plc (NYSE: PSO) was upgraded to Outperform from Neutral at Credit Suisse.
  
• Dell (NASDAQ: DELL) was upgraded to Conviction Buy from Neutral at Goldman.
  
• Nymagic (NYSE: NYM) was upgraded to Market Perform from Underperform at Keefe Bruyette.

• Citigroup upgraded shares of Consol Energy (NYSE: CNX) to Buy from Hold following the company's lowered guidance as 2009 is fully contracted with a 26% price increase. The firm raised its target to $40 from $38.
  
• Deutsche Bank upgraded AstraZeneca (NYSE: AZN) to Buy from Hold on valuation as it thinks the sell-off on the company's Q4 miss and cautious guidance is overdone.
  
• Wachovia upgraded Boston Scientific (NYSE: BSX) to Outperform from Market Perform because the firm thinks the outlook of the company's two main markets is improving. The firm believes the company's valuation is attractive. Thomas Weisel upgraded Boston Scientific to Overweight from Market Weight citing valuation and improving fundamentals.
• Goldman added MasterCard (NYSE: MA) to the Conviction Buy List.
  
• Accuray (NASDAQ: ARAY) was raised to Buy from Neutral at Piper Jaffray.
  
• KLA-Tencor (NASDAQ: KLAC) was upgraded to Buy from Neutral at Banc of America/Merrill.